


Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan



We constructed a Markov microsimulation model among hypothetical cohorts of community-dwelling older osteoporotic Japanese women without prior hip or vertebral fractures.

Subcutaneous denosumab every 6 months for 5 years was cost-saving or cost-effective, compared with weekly oral alendronate for 5 years.

References: Mori et al., *Osteoporosis International* (2017) 28: 1733–1744

Contact: Takahiro Mori, MD MSHS PhD, Associate Professor at the University of Tsukuba